Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Summarized Financial Information of Discontinued Operations (Details) - USD ($) $ in Millions			12 Months Ended
		Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Costs and expenses:
Discontinued operations––net of tax			$ 6	$ (434)	$ 2,529
Certain legal matters, net	[1]		230	182	28
Discontinued Operations [Member]
Income Statement Disclosures
Revenues	[2]		0	277	7,572
Costs and expenses:
Cost of sales	[2]		0	204	2,106
Selling, informational and administrative expenses	[2]		8	26	1,682
Research and development expenses	[2]		0	9	224
Acquired in-process research and development expenses	[2]		0	0	0
Amortization of intangible assets	[2]		0	45	224
Restructuring charges and certain acquisition-related costs	[2]		0	2	29
Other income	[2]		(20)
Other expense	[2]			365	428
Pre-tax income/(loss) from discontinued operations	[2]		12	(375)	2,879
Provision/(benefit) for taxes on income	[2]		13	(107)	349
Income/(loss) from discontinued operations––net of tax	[2]		(1)	(268)	2,529
Pre-tax gain/(loss) on sale of discontinued operations	[2]		10	(211)	0
Provision/(benefit) for taxes on income	[2]		2	(44)	0
Gain/(loss) on sale of discontinued operations––net of tax	[2]		7	(167)	0
Discontinued operations––net of tax	[2]		$ 6	(434)	2,529
Discontinued Operations [Member] | Upjohn Inc and Upjohn Finance B.V. [Member]
Costs and expenses:
Interest expense					116
Discontinued Operations [Member] | Upjohn Finance B. V.
Costs and expenses:
Pre-tax charges related to remeasurement of Euro debt					$ 223
Discontinued Operations, Disposed of by Sale [Member] | Meridian [Member]
Costs and expenses:
Gain/(loss) on sale of discontinued operations––net of tax		$ (167)
Discontinued Operations, Disposed of by Sale [Member] | Meridian [Member] | Epi Pen [Member]
Costs and expenses:
Certain legal matters, net				$ 345

[1] 2022 primarily includes certain product liability and other expenses related to products discontinued and/or divested by Pfizer. 2021 primarily includes certain product liability expenses related to products discontinued and/or divested by Pfizer, and to a lesser extent, legal obligations related to pre-acquisition commitments.

[2] In 2022, Discontinued operations—net of tax relates to post-close adjustments. In 2021, Discontinued operations—net of tax primarily includes (i) the operations of Meridian prior to its sale on December 31, 2021 recognized in Income/(loss) from discontinued operations—net of tax, which includes a pre-tax amount to resolve a MDL relating to EpiPen against the Company in the U.S. District Court for the District of Kansas for $345 million; and (ii) the after tax loss of $167 million related to the sale of Meridian recognized in Gain/(loss) on sale of discontinued operations––net of tax. To a much lesser extent, Discontinued operations—net of tax in 2021 also includes the operations of the Mylan-Japan collaboration prior to its termination on December 21, 2020 and post-close adjustments directly related to our former Upjohn and Nutrition discontinued businesses, including adjustments for tax, benefits and legal-related matters recognized in Income/(loss) from discontinued operations—net of tax. In 2020, Discontinued operations—net of tax relates to the operations of the Upjohn Business, Meridian and the Mylan-Japan collaboration and includes the impact of the 2021 MTM change in accounting principle, pre-tax interest expense of $116 million associated with the U.S. dollar and Euro denominated senior unsecured notes issued by Upjohn Inc. and Upjohn Finance B.V. in the second quarter of 2020 and pre-tax charges of $223 million related to the remeasurement of Euro debt issued by Upjohn Finance B.V. in the second quarter of 2020.